Video Experimental Relacionado
Updated: Sep 10, 2025
11:06
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.2K
Dirigirse a la FXR en los hepatocitos: un enfoque prometedor para mejorar la fibrinólisis y reducir el riesgo de
1The First Affiliated Hospital of Xi'an Jiaotong University, Xi'An, China.
Blood
|August 27, 2025
Resumen
La obesidad aumenta el riesgo de trombosis venosa profunda (TVP) por el aumento del inhibidor del activador del plasminógeno 1 (IAP-1) en el hígado. La activación de la FXR en los hepatocitos reduce la PAI-1, mejora la fibrinólisis y reduce la carga de la TVP.
Área de la Ciencia:
- Enfermedad metabólica
- Hematología
- Biología molecular
Sus antecedentes:
- La obesidad es un factor de riesgo significativo para la enfermedad tromboembólica venosa (ETV).
- El inhibidor del activador del plasminógeno 1 (PAI-1) está relacionado con la obesidad y altera la fibrinólisis, pero su regulación en la obesidad no está clara.
- El hígado juega un papel crucial en la regulación de los niveles circulantes de PAI-1.
Objetivo del estudio:
- Investigar la regulación ascendente del PAI-1 en la obesidad.
- Determinar el papel de la PAI-1 en la fibrinólisis y la trombosis venosa profunda asociadas a la obesidad.
- Para explorar el potencial de la señalización FXR hepatocito para el beneficio terapéutico.
Principales métodos:
- Se utilizaron modelos de ratón con obesidad inducida por la dieta para estudiar la expresión de PAI-1 y la fibrinólisis.
- Se analizaron los datos de secuencia de ARN de células únicas de hígados humanos obesos para la señalización de FXR.
- Se realizaron estudios de activación e inhibición de la FXR en ratones y en hepatocitos primarios de ratón (HMP).
- Para evaluar la regulación de la transcripción se emplearon ensayos de reporter de doble luciferasa y de inmunoprecipitación de cromatina (Ch-IP).
- El tratamiento farmacológico con tropifexor se evaluó en ratones obesos.
Principales resultados:
- Los ratones DIO mostraron un aumento de la PAI-1 de los hepatocitos, tiempos de fibrinólisis más cortos y trombos venosos más grandes.
- La reducción de la señalización FXR de los hepatocitos se correlacionó con un aumento de la PAI-1 en el hígado humano obeso.
- La activación de FXR suprimió el ARNm de Serpine1 y la proteína PAI-1 en ratones y HMP.
- La activación de FXR reprimió directamente la transcripción de Serpine1.
- El tratamiento con Tropifexor en ratones obesos redujo la PAI-1 plasmática, mejoró la fibrinólisis y redujo la carga de TVP.
Conclusiones:
- La señalización de FXR en los hepatocitos es un regulador clave de la expresión de PAI-1.
- Dirigirse a la activación de la FXR hepática puede representar una nueva estrategia terapéutica para mejorar la fibrinólisis y reducir el riesgo de TVP en individuos obesos.
Videos de Conceptos Relacionados
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:16Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644